Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir for Prevention of Mother-to-Child HIV Transmission
NCT01854762Phase 3Terminated
- Sponsor
- Fundação Bahiana de Infectologia
- Start
- Jun 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of raltegravir in human immunodeficiency virus infection (HIV), sponsored by Fundação Bahiana de Infectologia. Primary endpoint: HIV Viral Load at Delivery. Started Jun 2015; status: terminated.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01854762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01854762.